Does this Biosimilar antibody have the same sequence as the therapeutic antibody?

The Biosimilar antibody has the same variable region and constant region sequence as the therapeutic antibody, except for Catalog numbers MAB9677, MAB9575, MAB9577, MAB9589, and their conjugates. These four antibodies have the same variable region as the Biosimilar, but not the same constant region.

What is a Biosimilar antibody?

A Biosimilar antibody is a non-therpeutic, recombinantly-expressed antibody which has the same sequence as the corresponding therapeutic antibody. It is for research use only. The nomenclature of the Biosimilar antibody includes the name of the therapeutic antibody. For example, Catalog # MAB9577 is called Human EGFR (Research Grade CetuxiMab Biosimilar) antibody.

Human VEGF (Research Grade Bevacizumab Biosimilar) Antibody

Catalog #: MAB9947 Datasheet / COA / SDS

Recombinant Monoclonal Antibody For Research Use Only

Catalog #	Availability	Size / Price	Qty
MAB9947-100
MAB9947-SP

Cell Proliferation Induced by VEGF165and Neutralization by Human VEGF (Bevacizumab Biosimilar) Antibody.

2 Images

All VEGF Antibodies

Product Details

Supplemental Products

Reviews

Summary Data Examples Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Human VEGF (Research Grade Bevacizumab Biosimilar) Antibody Summary

Species Reactivity

Human

Specificity

Detects human VEGF based on Bevacizumab therapeutic antibody. This non-therapeutic antibody uses the same variable region sequence as the therapeutic antibody Bevacizumab. This product is for research use only.

Source

Recombinant Monoclonal Human IgG₁ Clone # Hu101

Purification

Protein A or G purified from cell culture supernatant

Immunogen

Human VEGF-A

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Endotoxin Level

<0.10 EU per 1 μg of the antibody by the LAL method.

Label

Unconjugated

Applications

Recommended Concentration

Sample

Neutralization

Measured by its ability to neutralize VEGF₁₆₅-induced proliferation in HUVEC human umbilical vein endothelial cells. The Neutralization Dose (ND₅₀) is typically 10-80 ng/mL in the presence of 10 ng/mL Recombinant Human VEGF₁₆₅.

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Neutralization

View Larger

Cell Proliferation Induced by VEGF₁₆₅and Neutralization by Human VEGF (Bevacizumab Biosimilar) Antibody. Recombinant Human VEGF₁₆₅(Catalog # 293-VE) stimulates proliferation in HUVEC human umbilical vein endothelial cells in a dose-dependent manner (orange line) as measured by Resazurin (Catalog # AR002). Proliferation elicited by Recombinant Human VEGF₁₆₅(10 ng/mL) is neutralized (green line) by increasing concentrations of Human Anti-Human VEGF (Bevacizumab Biosimilar) Monoclonal Antibody (Catalog # MAB9947). The ND₅₀ is typically 10-80 ng/mL.

Reconstitution Calculator

Preparation and Storage

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: VEGF

Bevacizumab is a biosimilar directed against VEGF.

Long Name

Vascular Endothelial Growth Factor

Entrez Gene IDs

7422 (Human); 22339 (Mouse); 83785 (Rat); 281572 (Bovine); 403802 (Canine); 493845 (Feline); 30682 (Zebrafish)

Alternate Names

MVCD1; VAS; vascular endothelial growth factor A; Vascular permeability factor; Vasculotropin; VEGF; VEGFA; VEGF-A; VEGFMGC70609; VPF; VPFvascular endothelial growth factor

Product Datasheets

Product Datasheet

COA

SDS

Related Research Areas

FAQs

Does this Biosimilar antibody have the same sequence as the therapeutic antibody?
- The Biosimilar antibody has the same variable region and constant region sequence as the therapeutic antibody, except for Catalog numbers MAB9677, MAB9575, MAB9577, MAB9589, and their conjugates. These four antibodies have the same variable region as the Biosimilar, but not the same constant region.
What is a Biosimilar antibody?
- A Biosimilar antibody is a non-therpeutic, recombinantly-expressed antibody which has the same sequence as the corresponding therapeutic antibody. It is for research use only. The nomenclature of the Biosimilar antibody includes the name of the therapeutic antibody. For example, Catalog # MAB9577 is called Human EGFR (Research Grade CetuxiMab Biosimilar) antibody.

View all Antibody FAQs